-
Thematic Analysis
Genomics: FutureTech Series
Genomic innovation is accelerating the transition to faster diagnostics, scalable biomanufacturing, and precision therapies. GlobalData’s latest FutureTech Series: Genomics report delivers a comprehensive analysis of the technologies redefining molecular healthcare. The report highlights automated DNA extraction, metagenomic pathogen detection, genome-edited iPSC therapies, plasmid DNA extraction kits, and isothermal DNA amplification, each positioned to address critical challenges in clinical reliability, decentralized testing, and therapeutic accessibility. Using GlobalData’s proprietary Tech Foresights platform, the report examines innovation drivers, challenges, patent leadership, and real-world...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, October 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Thematic Analysis
Energy Transition Strategies of Oil and Gas Contractors: Strategic Intelligence
Contractors would play a pivotal role in enabling their clients-primarily oil & gas companies-to implement sustainable energy solutions. All major contractors have announced strategies for cutting their emissions to fulfill the decarbonization pledges of their headquartered countries. Contractors are turning to low-carbon energy sources-including hydrogen, renewable power, and bioenergy-to achieve net zero in Scope 1 and Scope 2 emissions. Contractors are also expanding their portfolio offerings to include core technologies, such as carbon capture, utilization and storage (CCUS), energy recovery,...
-
Track & Monitor
UKPS Market Impact - AI in Central Government
Market Impact - UK Public Sector: AI in Central Government is an overview of the state of artificial intelligence deployments in UK central government including current use cases and recommendations to technology suppliers
-
Q3 2025 CRO Activity and Intel Report
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q3 2025.
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, September 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Wind Power Market Analysis by Key Countries, Average Turbine Size and Share, Technology, Installed Capacity, and Forecast to 2035
“Wind Power Market, Update 2025 – Global Market Size, Turbine Market Share, Average Turbine Size, and Key Country Analysis to 2035” is the latest market analysis report from GlobalData, the industry analysis specialist. The report provides a clear overview of and detailed insight into the global wind power market. The report provides data and analysis on the historic and forecasts of wind power capacity and generation, geo-political scenario, market size, and market drivers and challenges for twelve key wind power...
-
Thematic Analysis
China's Evolution in Global Drug Development and Clinical Trials: Strategic Intelligence
In 2015, China’s state council launched ‘Opinions on Deepening the Reform of the Review and Approval Processes to Encourage Innovation of Drugs and Medical Devices,’ which was the catalyst of change to implement several regulatory frameworks to encourage domestic innovation, expedite drug approvals, and enhance China’s presence on the global pharmaceutical stage. The US has the largest share of global drugs in development at 40%, China has 20%, and the 5EU (France, Germany, Italy, Spain, and the UK) has 11%...
-
Thematic Analysis
China's Licensing Trends Shaping Global Drug Development: Strategic Intelligence
Over the past five years, China’s biotech sector’s out-licensing deals have increased significantly. Between 2020 and 2024, the compound annual growth rate (CAGR) was approximately 21.7% for licensing agreements, which is a significant increase highlighting the strength of innovative drugs coming from China. This can be attributed to accelerated regulatory reforms, resulting in streamlined drug approvals and extended market exclusivity. Oncology accounted for 59% of these deals and made up 52% of the total deal value during this time period....
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, August 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.